A pilot study of indigenously manufactured HCAR19 (2nd generation Anti-CD19-41BB- CD3ζ chimeric antigen receptor T-cell therapy) in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talicabtagene autoleucel (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

30 Jan 2024 New trial record
12 Dec 2023 Pooled results from Phase I and a planned interim analysis of the Phase II study evaluating Actaly-celpresented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight